AmerisourceBergen's most recent trend suggests a bearish bias. One trading opportunity on AmerisourceBergen is a Bear Call Spread using a strike $75.50 short call and a strike $80.50 long call offers a potential 17.65% return on risk over the next 9 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $75.50 by expiration. The full premium credit of $0.75 would be kept by the premium seller. The risk of $4.25 would be incurred if the stock rose above the $80.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for AmerisourceBergen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for AmerisourceBergen is bearish.
The RSI indicator is at 34.81 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for AmerisourceBergen
Edited Transcript of ABC earnings conference call or presentation 2-Nov-17 12:30pm GMT
Sat, 04 Nov 2017 00:01:12 +0000
Q4 2017 AmerisourceBergen Corp Earnings Call
AmerisourceBergen expects tumbling generic drug prices to settle
Thu, 02 Nov 2017 17:15:54 +0000
AmerisourceBergen Corp said it expects stubbornly low generic drug prices, which have plagued drugmakers and wholesalers, to not deteriorate further next year, and brushed off concerns about Amazon's possible entry into the industry. The drug distributor ended its fiscal year with a quarterly loss as it set aside $575 million for legal costs for a lawsuit that alleged its unit sold pre-filled syringes of cancer drugs prepared in ways that violated federal rules. Settlement talks on the civil lawsuit are still on.
AmerisourceBergen (ABC) Beats Q4 Earnings, Issues FY18 View
Thu, 02 Nov 2017 14:33:02 +0000
Solid growth in the Pharmaceutical Distribution Services segment drove AmerisourceBergen's (ABC) top line in the fourth quarter.
AmerisourceBergen (ABC) Beats on Earnings in Q4, Sales Miss
Thu, 02 Nov 2017 11:59:11 +0000
AmerisourceBergen's (ABC) strong performance in the Pharmaceutical Distribution Services segment is a positive. The company issued guidance for fiscal 2018.
AmerisourceBergen posts loss on $592 mln charge
Thu, 02 Nov 2017 10:43:15 +0000
Drug distributor AmerisourceBergen Corp on Thursday posted a fourth-quarter net loss as it took a $592 million charge related to litigation and employee severance costs. Net loss was $294.6 million, or …
Related Posts
Also on Market Tamer…
Follow Us on Facebook